A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Trial end date:
2013-11-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if GSK2402968 is effective in the treatment of
ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be
corrected by exon 51 skipping. Two doses of GSK2402968 and placebo will be used in this
study.